A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.

D G Evans, S M Huson, D Donnai, W Neary, V Blair, V Newton, T Strachan, R Harris

Department of Medical Genetics, St Mary's Hospital, Manchester.

The major defining features, age at onset of symptoms, and survival in 150 patients with type 2 neurofibromatosis (NF2) have been studied. The mean age at onset was 21.57 years (n = 110) and no cases presented after 55 years of age. Patients presented with symptoms attributable to vestibular schwannomas (acoustic neuroma), cranial meningiomas, and spinal tumours. In 97 cases studied personally by the authors, skin and eye examination were found to be useful to detect early signs of the condition. Examination of the skin is likely to assist in early diagnosis in at least 10% of cases and examination of the eye for a lens opacity or cataract in at least as many again. There are marked interfamilial differences in disease severity and tumour susceptibility. Vestibular schwannomas are not fully penetrant, but the condition is usually expressed in another way. Alteration to the current diagnostic criteria is advocated to cover the lack of provision for new mutations. A screening protocol is proposed and the effect of disease heterogeneity on management is discussed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hadfield, K D, Newman, W G, Bowers, N L, Wallace, A, Bolger, C, Colley, A, McCann, E, Trump, D, Prescott, T, Evans, D G R (2008). Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J. Med. Genet. 45: 332-339 [Abstract] [Full Text]  
• Lee, J. Y., Kim, H., Ryu, C. H., Kim, J. Y., Choi, B. H., Lim, Y., Huh, P.-W., Kim, Y.-H., Lee, K.-H., Jun, T.-Y., Rha, H. K., Kang, J.-K., Choi, C. R. (2004). Merlin, a Tumor Suppressor, Interacts with Transactivation-responsive RNA-binding Protein and Inhibits Its Oncogenic Activity. J. Biol. Chem. 279: 30265-30273 [Abstract] [Full Text]  
• Baser, M. E., Friedman, J. M., Wallace, A. J., Ramsden, R. T., Joe, H., Evans, D. G.R. (2002). Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759-1765 [Abstract] [Full Text]  
• Sun, C.-X., Haipek, C., Scoles, D. R., Pulst, S. M., Giovannini, M., Komada, M., Gutmann, D. H. (2002). Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 11: 3167-3178 [Abstract] [Full Text]  
• Sperfeld, A. D., Hein, C., Schroder, J. M., Ludolph, A. C., Hanemann, C. O. (2002). Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 125: 996-1004 [Abstract] [Full Text]  
• Kalamarides, M., Niwa-Kawakita, M., Leblois, H., Abramowski, V., Perricaudet, M., Janin, A., Thomas, G., Gutmann, D. H., Giovannini, M. (2002). Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 16: 1060-1065 [Abstract] [Full Text]  
• Gutmann, D. H., Haipek, C. A., Burke, S. P., Sun, C.-X., Scoles, D. R., Pulst, S. M. (2001). The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility. Hum Mol Genet 10: 825-834 [Abstract] [Full Text]  
• Bruder, C. E.G., Hirvela, C., Tapia-Paez, I., Fransson, I., Segraves, R., Hamilton, G., Zhang, X. X., Evans, D. G., Wallace, A. J., Baser, M. E., Zucman-Rossi, J., Hergersberg, M., Boltshauser, E., Papi, L., Rouleau, G. A., Poptodorov, G., Jordanova, A., Rask-Andersen, H., Kluwe, L., Mautner, V., Sainio, M., Hung, G., Mathiesen, T., Moller, C., Pulst, S. M., Harder, H., Heiberg, A., Honda, M., Niimura, M., Sahlen, S., Blennow, E., Albertson, D. G., Pinkel, D., Dumanski, J. P. (2001). High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10: 271-282 [Abstract] [Full Text]  
• Evans, D G. R, Sainio, M, Baser, M. E (2000). Neurofibromatosis type 2. J. Med. Genet. 37: 897-904 [Abstract] [Full Text]  
• EVANS, D G R, NEWTON, V, NEARY, W, BASER, M E, WALLACE, A, MACLEOD, R, JENKINS, J P R, GILLESPIE, J, RAMSDEN, R T (2000). Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J. Med. Genet. 37: 944-947 [Full Text]  
• Trivedi, R., Byrne, J., Huson, S. M, Donaghy, M. (2000). Focal amyotrophy in neurofibromatosis 2. J. Neurol. Neurosurg. Psychiatry 69: 257-261 [Abstract] [Full Text]  
• Evans, D G R, Birch, J M, Ramsden, R T (1999). Paediatric presentation of type 2 neurofibromatosis. Arch. Dis. Child. 81: 496-499 [Abstract] [Full Text]  
• Evans, D G R, Lye, R, Neary, W, Black, G, Strachan, T, Wallace, A, Ramsden, R T (1999). Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J. Neurol. Neurosurg. Psychiatry 66: 764-767 [Abstract] [Full Text]  
• Briggs, R. J. S., Brackmann, D. E., Baser, M. E., Hitselberger, W. E. (1994). Comprehensive Management of Bilateral Acoustic Neuromas: Current Perspectives. Arch Otolaryngol Head Neck Surg 120: 1307-1314 [Abstract]  
• MacCollin, M., Mohney, T., Trofatter, J., Wertelecki, W., Ramesh, V., Gusella, J. (1993). DNA Diagnosis of Neurofibromatosis 2: Altered Coding Sequence of the merlin Tumor Suppressor in an Extended Pedigree. JAMA 270: 2316-2320 [Abstract]